Diversified Consumer Services
Company Overview of Baylor College of Medicine
Baylor College of Medicine is an education, research, and patient care institution that comprises Neurology, Neuroscience, Neurosurgery, Obstetrics and Gynecology, Ophthalmology, Orthopedic Surgery, Otorhinolaryngology & Communicative Sciences, Pathology, Pediatrics, Pharmacology, and Cardiovascular Sciences, Dermatology, and Developmental Biology departments. It also consists of Center for Cell and Gene Therapy, Center for Medical Ethics and Health Policy, Children's Nutrition and Research Center, Huffington Center on Aging, and Winters Center. Baylor College of Medicine was founded in 1900 and is based in Houston, Texas. It has endowment assets worth $ 1.44 billion.
One Baylor Plaza
Mail Stop 160
Houston, TX 77030
Founded in 1900
Key Executives for Baylor College of Medicine
Chief Executive Officer and President
Chairman of the Department of Neurology
Executive Vice President and Executive Dean
Senior Vice President and Dean of Research
Compensation as of Fiscal Year 2015.
Baylor College of Medicine Key Developments
Biocept Announces Collaboration with Baylor College of Medicine to Develop Liquid Biopsy Tests for Estrogen Receptor Gene
Dec 7 15
Biocept, Inc. announced a collaboration with Baylor College of Medicine to develop minimally invasive blood-based tests using Biocept's circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) molecular diagnostic assay platforms to detect mutations in the estrogen receptor gene (ESR1). Clinical studies have shown that endocrine therapy treatment can significantly reduce breast cancer-related mortality for patients with estrogen receptor (ER) positive breast cancers. However, nearly one-third of women treated with Tamoxifen and other endocrine therapies become resistant to these therapies. Recent studies utilizing next-generation sequencing on estrogen receptor-positive, metastatic patient samples indicate that recurrent ESR1 mutations, which may play an important role in acquired endocrine therapy resistance, are far more frequent than previously thought. As a results, ESR1 mutations are becoming important biomarker targets as an indicator for therapy resistance and could serve as a companion diagnostic to cancer therapeutics currently in development that address this acquired form of resistance. Surgical tumor biopsies are typically used to evaluate the presence of ESR1 mutations. However, these invasive surgical procedures are not always practical for monitoring as they can add risk and are sometimes not possible due to the patient's health. Additionally, tissue biopsy may not be sufficient to detect these mutations due to tumor heterogeneity or differences in the tumor's makeup that may not be detected by a single tissue sample.
Baylor College Of Medicine Inc. Wins $2,390,148 Federal Contract
Sep 11 15
National Institutes of Health (Department of Health and Human Services), National Institute of Child Health and Human Development, has awarded a Base: $788,526 /Option 1: $725,211 /Option 2: $876,411 /Total: (Base + Options) $2,390,148 federal modified contract on Sept. 10, 2015 for Fetal Body Composition and Volumes Study to Baylor College Of Medicine Inc.
DNAnexus and the Human Genome Sequencing Center at Baylor College of Medicine Collaborate to Develop and Globally Deploy Comprehensive Clinical Whole Genome Analysis Platform
Jun 22 15
DNAnexus announced a collaboration with The Human Genome Sequencing Center at Baylor College of Medicine, to co-develop HgV, the next generation of the HGSC’s Mercury solutions pipeline. HgV is a comprehensive framework for large-scale high-throughput whole genome sequence analysis in the settings of precision medicine research and clinical applications. The HGSC’s Mercury pipeline is the core data-processing and variant-calling tool for the cloud-based genome analysis projects, including the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the Alzheimer’s Disease Sequencing Project, and the Baylor-Hopkins Center for Mendelian Genomics. This pipeline is used in clinical studies to identify mutations from genomic data to determine the significance of these mutations as a cause of serious disease. HGSC continues to be at the forefront of technical innovation and bioinformatics development. Partnering with DNAnexus, HGSC’s team of bioinformatics experts have expanded their capability for rapid development and deployment of HgV to the broader research community via the leading cloud-based bioinformatics platform – DNAnexus. HgV is optimized for Illumina X Ten levels of throughput and whole-genome data processing, analytics, and collaboration. Drawing on extensive R&D of high-quality personal genomes and large disease cohorts, this platform will provide an improved alternative to existing methods and multiple protocols for comprehensive whole genomes: 'Parliamentary' approach to the discovery and evaluation of large, structural variants inaccessible to targeted genome sequencing, multi-source functional whole-genome annotation of both protein-coding and non-coding regions, aggregation of annotation, phenotype, and variant information in a NoSQL-based extensible and scalable data warehouse, integration of heterogeneous library protocols and sequencing platforms, including long-read sequencing and SNP arrays, project-specific 'Afterburners', such as variant prioritization for Mendelian Diseases, pedigree sample sets, de novo mutation analysis in trios, cancer, and case/control studies. As the cost of whole genome sequencing (WGS) continues to decline and the quality increases, its use for novel discovery and to identify genetic disorders in the clinic is becoming routine. Although most identified disease-causing variants fall within the exome, WGS can identify non-coding variants and large, structural variants that may contribute to complex and common diseases, especially in cases that have proven elusive to exome analysis. DNAnexus sits at the forefront of cloud-based data security, compliance and controlled access. By co-developing with DNAnexus, the HGSC can deploy HgV into an investigative environment while leveraging extensive research experience. These efforts include establishing an exceptionally high-quality personal genome for testing, benchmarking and validating protocols, methods and tools. The raw sequence data from multiple platforms have been subject to deep variant calling, trio analysis, whole genome assembly, long-read structural variant analysis, and Mendelian prioritization, generating high-quality variants that can be used for future tool validation. HgV development includes specific emphasis on trackability, versioning and reproducibility to enable seamless transition into a CAP/CLIA environment. HgV is an open-source and fully configurable platform that will be equipped with pre-configured DNAnexus workflows for various use cases, including optimized speed, sensitivity, and accuracy. Designed with the Illumina HiSeq X Ten platform in mind, it provides a secure and scalable environment for single samples and multi-sample projects, allowing users to focus on interpreting their data rather than local IT infrastructure and data logistics. Through DNAnexus, this Data Commons model serves as a global framework for developers and downstream users to implement new methods, share data, provide feedback, and identify new collaborations.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|